

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Mind the gap - atrial fibrillation patients and their physicians perceive risk and benefits of stroke prevention differently

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018242
Article Type:	Research
Date Submitted by the Author:	16-Jun-2017
Complete List of Authors:	Zweiker, David; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Zweiker, Robert; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Roesch, Konstantina; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Schumacher, Martin; Krankenhaus Barmherzige Bruder Graz, Department of Internal Medicine Stepan, Vinzenz; Krankenhaus der Elisabethinen, Department of Internal Medicine Krippel, Peter; Landeskrankenhaus Furstenfeld, Department of Internal Medicine Bauer, Norbert; Landeskrankenhaus Hartberg, Department of Internal Medicine Heine, Martin; Landeskrankenhaus Feldbach, Department of Neurology Reicht, Gerhard; Krankenhaus Barmherzige Bruder Graz-Eggenberg Zweiker, Gudrun; General Practitioner Sprenger, Martin; Medizinische Universitat Graz, Department of Social Medicine and Epidemiology Watzinger, Norbert; Landeskrankenhaus Feldbach, Department of Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Anticoagulation < HAEMATOLOGY, CARDIOLOGY, Cardiology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 **Mind the gap - atrial fibrillation patients and their**
5
6
7 **physicians perceive risk and benefits of stroke prevention**
8
9
10 **differently**
11
12

13 David Zweiker¹, Robert Zweiker¹, Konstantina Roesch¹, Martin Schumacher²,
14 Vinzenz Stepan³, Peter Krippel⁴, Norbert Bauer⁵, Martin Heine⁶, Gerhard Reicht⁷,
15 Gudrun Zweiker⁸, Martin Sprenger⁹, Norbert Watzinger^{10*}
16
17
18
19
20

21 ¹ Division of Cardiology, Department of Internal Medicine, Medical University of Graz,
22 Graz, Austria
23

24 ² Department of Internal Medicine, Hospital Barmherzige Brueder Marschallgasse,
25 Graz, Austria
26
27

28 ³ Department of Internal Medicine, Hospital Elisabethinen, Graz, Austria
29

30 ⁴ Department of Internal Medicine, LKH Fürstenfeld, Krankenhausverbund Feldbach-
31 Fürstenfeld, Fürstenfeld, Austria
32
33

34 ⁵ Department of Internal Medicine, LKH Hartberg, Hartberg, Austria
35
36

37 ⁶ Department of Neurology, LKH Feldbach, Krankenhausverbund Feldbach-
38 Fürstenfeld, Feldbach, Austria
39
40
41

42 ⁷ Department of Internal Medicine, Hospital Barmherzige Brueder Eggenberg, Graz,
43 Austria
44
45

46 ⁸ General Practitioner, Straden, Austria
47

48 ⁹ Department of Social Medicine and Epidemiology, Medical University of Graz, Graz,
49 Austria
50
51

52 ¹⁰ Department of Internal Medicine, LKH Feldbach, Krankenhausverbund Feldbach-
53 Fürstenfeld, Feldbach, Austria
54
55
56
57
58
59
60

1
2
3 * Corresponding author:

4 Norbert Watzinger, MD

5 Department of Internal Medicine, LKH Feldbach

6
7 Krankenhausverbund Feldbach-Fürstenfeld

8
9 Ottokar-Kernstock-Strasse 18

10
11 8330 Feldbach

12
13 Austria

14
15 email: norbert.watzinger@lkh-feldbach.at

16
17 phone: +43 3152 899 3201

18
19 fax: +43 3152 899 3209

Abstract

Objective

Since more than 20 years, oral anticoagulation (OAC) is state-of-the-art therapy for atrial fibrillation (AF), the most common arrhythmia worldwide. However, little is known about the perception of AF patients and how it correlates with risk scores used by their physicians. Therefore, the objective of our study was to correlate patients' estimates of their own stroke and bleeding risk with the objectively predicted individual risk using CHA₂DS₂-VASc and HAS-BLED scores.

Design

Cross-sectional prevalence study using convenience sampling.

Settings

Nine hospitals (first, secondary and tertiary care) and one general practitioner in Austria. Patients' perception of stroke and bleeding risk was opposed to commonly used risk scoring.

Participants

Patients with newly diagnosed AF and indication for anticoagulation.

Main Outcome Measures

Comparison of subjective risk perception with CHA₂DS₂-VASc and HAS-BLED scores showing possible discrepancies between subjective and objective risk estimation. Patients' judgement of their own knowledge on AF and education were also correlated with accuracy of subjective risk appraisal.

Results

Ninety-one patients (age 73 ± 11 years, 45% female) were included in this study. Subjective stroke and bleeding risk estimation did not correlate with risk scores ($\rho=0.08$, $\rho=0.47$ and $\rho=0.17$, $\rho=0.15$). The majority of patients (57%) underestimated the individual bleeding risk. Patients feared stroke more than bleeding (67% vs. 10%). There was no relationship between accurate perception of stroke and bleeding risks and education level ($\rho=-0.06$, $\rho=0.63$ and $\rho=0.17$, $\rho=0.15$). However, we found a correlation between the patients' judgement of their own knowledge of AF and correct assessment of individual stroke risk ($\rho=0.24$, $\rho=0.02$).

Conclusions

In this cross-sectional analysis of OAC-naïve AF patients, we found major differences between patients' perceptions and physicians' assessments of risks and benefits of OAC. To ensure shared decision-making and informed consent, more attention should be given to evidence-based and useful communication strategies.

Trial registration

NCT03061123

Key words

Atrial fibrillation, oral anticoagulation, questionnaire, self-assessment

Article summary

Strengths and limitations

- The design of this cross-sectional study allowed the objective assessment of the patients' risk perception immediately after initiation of anticoagulation for atrial fibrillation.
- For generalizability, primary, secondary and tertiary health care centres were included in this study.
- The low sample size is the main limitation of this study.

Introduction

Atrial fibrillation (AF) is the most common significant arrhythmia worldwide, associated with a fivefold increase in risk for stroke¹ and almost doubles of mortality.² In an ageing population, the number of individuals affected is projected to increase exponentially over the next decades.³ Since the early 1990ies, oral anticoagulation (OAC) is the state-of-the-art therapy for reducing stroke and embolic events.² OAC is considered a long-term, often lifelong medical intervention. Therefore, clinicians and particularly patients need to have a clear understanding of the related benefits and immanent harms.⁴ It serves as reasonable background for shared-decision making of patients and their doctors, one of the most important principles for patients' reliance, compliance and adherence to recommended medical strategies.^{5 6}

Adequate information of patients⁷ and increased health literacy^{8 9} are of major importance for compliance and adherence to therapy. Patients' knowledge also affects the perception of risk for stroke, embolic events and bleeding. It has been shown that the extent of information perceived influenced patients' preferences towards or against OAC treatment the most.¹⁰

Clinicians use algorithms like CHA₂DS₂-VASc and HAS-BLED scores¹¹⁻¹³ to predict the balance of future risk for stroke and embolic events versus bleeding in an individual patient. A recent survey of the European Heart Rhythm Association proved that a considerable amount of time and resources are needed in daily clinical practice to communicate risk / benefit ratios to patients suffering from AF: Several centres have established special OAC clinics and initial visits mostly lasted 21-30 minutes.¹⁴ However, decades after the introduction of OAC therapy, standardised and validated risk communication tools¹⁵⁻¹⁷ are still missing and adherence follow-up programmes

1
2
3 are rare.¹⁴ Those programmes have an important impact on effectiveness of OAC:
4
5 Adherence to OAC is considered a key factor for preventing events,¹⁸ but it is still as
6
7 low as 43%.¹⁹
8
9

10 Little is known about the perception of AF patients and how it correlates with risk
11
12 scores used by their physicians.²⁰ A potential gap between subjective and objective
13
14 assessments may increase the likelihood of non-compliance to OAC in AF patients.²¹
15
16 Therefore, the study was designed to correlate the subjective stroke and bleeding
17
18 risk with the objectively predicted individual risks calculated by CHA₂DS₂-VASc and
19
20 HAS-BLED scores.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

This work is a cross-sectional prevalence study, using convenience sampling by trained doctors at 10 centres (representing primary, secondary and tertiary health care) in the province of Styria, Austria. Responsible institutional review boards approved the study (1376/2015 [BHB Graz, Austria], 28-004 ex 15/16 [Medical University of Graz, Austria]) Furthermore, the study was registered under the ClinicalTrials.gov number NCT03061123. Patients with first diagnosed and ECG-documented non-valvular AF and indication for OAC were included in the study. Exclusion criteria were pre-existing OAC therapy, valvular heart disease, history of valve surgery, denial or inability of informed consent.

This study was designed to comply with standard operating procedures of individual centres for initiation of OAC therapy. Responsible physicians carried out pre-treatment interviews, including discussion of benefits, harms and side effects of OAC. After informed consent was signed, a standardized questionnaire was handed out to all patients (supplemental figure S1).

Questionnaire

The survey was conducted using a standardized questionnaire with two parts (supplemental table S1). The patient-oriented part consisted of seven questions covering subjective perception of patients with regard to general individual risk/benefit ratios of OAC in AF, the willingness of therapy continuation even in the possible case of minor adverse effects (haematoma, minor bleeding) and the individually discerned level of information. We used 3- and 4-point verbal rating scales to comply with the patients' categorical perception of checks and balances.²²

1
2
3 Physicians in charge of patients filled the second part, which included patient
4 demographics, CHA₂DS₂-VASc and HAS-BLED scores, as well as the intended OAC
5 therapy.
6
7

8
9
10 CHA₂DS₂-VASc and HAS-BLED scores were stratified into four risk categories each
11 corresponding to the four different risk levels for stroke/embolic events and bleeding
12 interrogated by the patient questionnaire. Risk estimations were based on published
13 data from large population studies. Regarding CHA₂DS₂-VASc score, patients with
14 zero points (stroke rate 0-1%/year) were considered *low risk*, one point (stroke rate 1-
15 2%/year) *intermediate risk*, 2-4 points (stroke rate 2-7%) *high risk* and ≥ 5 points
16 (stroke rate $> 7\%$ /year) *very high risk* cohort.^{11 23 24} The corresponding categories
17 concerning HAS-BLED score were as follows: no or one risk factor (*low risk* group,
18 bleeding rate 0-4%/year), two risk factors (*intermediate risk* group, bleeding rate 4-
19 6%/year), 3 or 4 risk factors (*high risk* group, bleeding rate 6-10%/year) and 5 or
20 more risk factors (*very high risk* group, bleeding rate $> 10\%$ /year).^{12 23}
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 For assessing the awareness of general benefit of OAC, we asked patients to
37 estimate their appraisal of relative risk reduction (RRR) for stroke and embolic
38 events. We defined *high* (RRR 50-74%) as accurate answer,²⁵ others were *low* (RRR
39 0-24%), *intermediate* (RRR 25-49%) and *very high* (RRR 75-100%). We extrapolated
40 predicted hazard ratios (HR) of bleeding due to OAC from meta-analyses²⁵⁻²⁸ and
41 defined the general risk of OAC as *intermediate* (HR 1.25-1.49). Other options were
42 *low* (HR 1.00-1.24), *high* (HR 1.50-2.00) and *very high* (HR > 2.00). Subjective scales
43 were interpreted as "correct" if they corresponded correctly to individual objective risk
44 groups.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analysis

Sample size calculation

Sample size calculation was performed using the freeware tool G*Power by Heinrich Heine University Düsseldorf (<http://www.gpower.hhu.de>). We sought to oppose the self-reported benefits and risks of OAC with an actual assessment using validated data (including CHA₂DS₂-VASc Score and HAS-BLED Score). To prove correlation ($|\rho| < 0.3$) with type I error (α) of 0.05 and power ($1 - \beta$) of 80%, at least 84 patients had to be included into the study.

Univariate analysis

Two-sided significance level was 0.05. Data are presented as mean \pm standard deviation, median (interquartile range) or count (proportion), where appropriate. Pearson's test and Spearman's rank correlation coefficient were used to correlate ordinal variables (e.g. subjective perceptions and risk scores). Correlation coefficients (i.e. $|r|$, $|\rho|$) were interpreted as follows: negligible correlation (0.0-0.3), low correlation (0.3-0.5), moderate correlation (0.5-0.8) and strong correlation (0.8-1.0).²⁹

Data were analysed with IBM® SPSS® Statistics version 23 (IBM Corporation, Armonk, NY).

Results

Patient population

From September 2015 to March 2016, 91 patients (age 73 ± 11 years, 45% female) from nine centres were included in this study (supplemental table S3). As highest educational attainment, lower secondary education (ISCED level 2, $n=32$, 35%) and higher secondary vocational education (ISCED level 3B $n=25$, 28%) were most prevalent. New oral anticoagulants (NOACs) were used most frequently ($n=75$, 82%). vitamin K antagonists ($n=14$, 15%) and low-molecular weight heparin ($n=2$, 2%) were given to remaining patients.

Objective risk estimation

Median CHA₂DS₂-VASc-Score was 4 (interquartile range 2-5). Therefore, we summarized most patients on high risk for stroke or embolic event (CHA₂DS₂-VASc score 2-4, stroke risk 2-7%/year, figure 1). Most common risk factors were arterial hypertension and age > 75 years (table 1). In terms of HAS-BLED score, most of patients were in low (0-1 points, bleeding risk 0–4 %) and intermediate risk groups (2 points, bleeding risk 4–6 %; figure 1).

Perception of individual risk

Many patients ($n=41$, 45%) interpreted risk for stroke and embolic events in atrial fibrillation *in general* as *high to very high* (corresponding stroke risk 2-7% and >7% per year, respectively). Bleeding risk was estimated mainly as *intermediate* (corresponding bleeding risk 4-6% per year, $n=40$, 44%). Patients feared stroke more than bleeding (67% vs. 10%) and only 9% would discontinue OAC therapy if minor

1
2
3 bleeding complications (e.g. epistaxis) would occur. Patients estimated their personal
4
5 level of information as *good* or *adequate* in 41% and 34%, respectively.
6
7

8 **Correlations**

9
10
11 Patients estimated their risk for stroke or embolic events in concordance to the
12
13 individual CHA₂DS₂-VASc score in 25 (28%) of cases, by the majority (n=52, 57%)
14
15 risk was underrated. Bleeding risk was assumed accurately in 37% (n=41), but
16
17 overestimated in 31 cases (34%). There were no significant correlations neither
18
19 between objectively assessed and subjectively expected risk for stroke nor for
20
21 bleeding ($p=0.08$, $p=0.47$, figure 2 and $p<0.01$, $p=0.98$, figure 3).
22
23
24
25

26 Analogies in patients' answers and CHA₂DS₂-VASc and HAS-BLED scores did not
27
28 correlate to the levels of highest education ($p=-0.06$, $p=0.64$ and $p=0.17$, $p=0.15$).
29
30 However, we observed a significant correlation between patients' judgement of their
31
32 knowledge of AF with regard to concordant assumptions of stroke risk and CHA₂DS₂-
33
34 VASc score ($p=0.24$, $p=0.02$, figure 4). No correlation was observed between
35
36 patients' judgement of AF knowledge and concordance with subjectively assumed
37
38 and objectively predicted risk for bleeding events ($p=0.08$, $p=0.45$).
39
40
41
42

43 **Perception of general risk**

44
45
46 Most patients (n=51, 56%) assumed score-predicted effectiveness of OAC in AF as
47
48 *high* (corresponding stroke risk reduction 50-74%). Other answers were *very high*
49
50 (RRR 75-100%; n=23, 25%), *intermediate* (RRR 25-49%; n=15, 17%) or *low* (RRR 0-
51
52 24%; n=1, 1%). The estimated general risk of bleeding caused by OAC was
53
54 considered by patients as *intermediate* (HR for bleeding 1.25-1.49; n=37, 41%) and
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

low (HR 1.00-1.24; n=30, 33%). Only 3 patients (3%) estimated the bleeding risk associated with OAC as *very high* (HR > 2.00).

For peer review only

Discussion

This cross-sectional questionnaire study in 91 OAC-naïve patients with non-valvular AF shows that (1) patients generally underestimated their risk of stroke, (2) they perceived their individual stroke risk to higher extent than bleeding risk and (3) there was a significant correlation between accuracy in answers and patients' judgement of their knowledge of AF.

Due to the high prevalence of AF in the western world, non-adherence to OAC in AF patients has a tremendous impact on our society. Despite the availability of adequate therapy, AF-related strokes are still estimated to cost eight billion USD annually in the United States^{30 31} or over 9,000 pounds per stroke in the UK.³² The increased severity of AF-related strokes compared to other etiologies³³ may even increase the negative effect of general embolic events on quality of life.³⁴ As a consequence, it is urgently necessary to ameliorate adherence to OAC therapy for AF. We proved underjudgement of stroke risk and therefore postulate better patient education as possibility to overcome this problem.

No correlation between subjective assessment and objective risk

To our knowledge, this is the first study that compares the subjective risk perception of AF patients with evidence-based risk scores used in daily clinical practice. We found no significant correlation between subjective and objective assessment of stroke or bleeding risk. Therefore, our study provides evidence that a perception gap remains after informed consent discussion before OAC initiation.

If this finding remains constant in larger trials, it has a direct impact on clinical practice. Such a perception gap is problematic at the start of a lifelong medical

1
2
3 intervention. It hinders not only shared decision making, but it also influences
4
5 treatment compliance and adherence.
6
7

8
9 Previous studies already evaluated the levels of information in patients after initiation
10 of OAC treatment.^{20 35-39} In a survey of 711 AF patients that were on OAC for at least
11 one year, only 7% knew the purpose of anticoagulation in AF.³⁸ Lane et al.³⁵
12 observed that 51% of AF patients with OAC therapy for ≥ 3 months could not name
13 their cardiac condition. Furthermore, the knowledge could not be increased by a brief
14 educational intervention. McCabe et al.⁴⁰ showed considerable knowledge deficits
15 already two weeks after initial diagnosis of AF. A recent qualitative systematic review
16 postulated the lack of patient information as one of the most important reasons for
17 VKA underuse.⁴¹
18
19

20
21 Although Dantas et al.³⁷ demonstrated that only minimal knowledge of patients is
22 needed to allow acceptance of OAC, doctors should seek shared decisions. This is
23 even more important, when evidence for drug treatment is marginal,⁴² which is
24 definitely not the case in patients with high risk scores for AF.² However, the
25 physician's perspective of shared decision making may not be congruent to the
26 patient's perceptions.⁴³ LaHaye et al.⁴⁴ demonstrated high interpatient variability
27 regarding individual treatment thresholds. Consequently, we propose that health
28 literacy of patients should be enhanced before OAC initiation, especially regarding
29 the individual risk/benefit ratio. Thus, patients may be able to participate in decision-
30 making of therapy initiation. Patients also seem to have difficulties regarding verbal
31 descriptions of risk.⁴⁵ Therefore, graphical information might help overcome this
32 problem.^{7 15} One promising example is an electronic prototype for the translation of
33 Grading of Recommendations Assessment, Development and Evaluation (GRADE)
34 summaries⁴⁶ into decision aids using interactive formats to present evidence
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 summaries at varying levels of detail.¹⁷ Another possibility is the establishment of a
4 Fact Box, which describes evidence of benefits and harms without making
5 recommendations.¹⁶ Further theory-driven educational interventions have been
6
7 shown to increase OAC control⁴⁷ or knowledge of INR targets.³⁵
8
9
10

11 12 ***Stroke is topping bleeding risk*** 13

14
15
16 In our study, most of the patients assumed their personal stroke risk to be the most
17 frequent and serious complication of untreated atrial fibrillation in their setting.
18
19 However, the majority (57%) underestimated their stroke risk while 41% interpreted
20 the bleeding risk accurately. In other studies, patients were keen on avoiding stroke
21 more than bleeding⁴⁸ and placed even more importance on stroke prevention than
22 doctors⁴⁹ with higher tolerance of adverse bleeding events.⁵⁰ With increased duration
23 of OAC therapy, knowledge about OAC in the indication of AF seems to deteriorate.³⁸
24
25
26
27
28
29
30
31

32 ***Factors influencing correct risk estimation*** 33

34
35
36 We found out that the highest level of educational attainment did not correlate with
37 analogies in risk estimation in our analysis. Our results therefore indicate that
38 understanding of individuals' risk is not correlated with formal education levels.
39
40 However, the preservation of knowledge might be correlated with better education.⁴⁰
41
42 Lip et al.³⁹ showed differences of AF perceptions in different ethnical groups. We
43 could not add evidence to this factor as we included only Caucasian patients.
44
45
46
47
48
49

50
51 Patients that felt better informed had an improved understanding of their individual
52 risks in this study. Consequently, we encourage to evaluate patients' information
53 level repeatedly by asking how informed they felt and to take appropriate measures
54
55 to enhance the patient's level of information if required.
56
57
58
59
60

Limitations

Our study has several limitations. Firstly, patient enrolment was not consecutive and therefore selection bias cannot be ruled out. Secondly, our sample size was not large enough for comparing differences between sites. Therefore, we cannot assess how differences in risk communication may have influenced our study results. Thirdly, we currently have no follow up data available. Therefore, we can only assume that higher levels of information might be associated with better adherence and outcomes as results of previous studies suggested. Fourthly, recent ESC guidelines do not endorse the HAS-BLED score any more as additional non-modifiable risk factors of bleeding have been established in the recent years. The HAS-BLED score is still propagated by the National Institute for Health and Clinical Excellence (NICE) guidelines.⁵¹ Lastly, we intended to concentrate on the risk perception of individual patients and did not evaluate the general knowledge of AF and stroke prevention per se in a standardized questionnaire.⁵² Due to this fact, we kept the questionnaire short and tried to minimize bias due to selection of motivated patients that may not be representative of the general AF population.²⁰

Conclusion

In this cross-sectional analysis of OAC-naïve AF patients, we found major differences between patients' perceptions and physicians' assessments of risks and benefits of OAC. To ensure shared decision-making and informed consent, more attention should be given to evidence-based and useful communication strategies.

Acknowledgements

We appreciate the helpful assistance of Mr. Stefan Zweiker in the preparation of the manuscript. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

Dr. Bauer reports personal fees from Bayer, Medtronic, Daiichi-Sankyo, Servier, personal fees from Bayer, AstraZeneca, other from Boehringer-Ingelheim, Bayer, Lilly, outside the submitted work.

Dr. Heine has nothing to disclose.

Dr. Krippel has nothing to disclose.

Dr. Reicht has nothing to disclose.

Dr. Schumacher has nothing to disclose.

Dr. Sprenger has nothing to disclose.

Dr. Stepan has nothing to disclose.

Dr. Watzinger reports personal fees from Lectures, personal fees from Consulting, outside the submitted work.

Dr. Zweiker D has nothing to disclose.

Dr. Zweiker G has nothing to disclose.

Dr. Zweiker R has nothing to disclose.

Contributorship statement

RZ, MS and NW designed the study.

RZ, KR, MS, VS, PK, NB, MH, GR, GZ, MS and NW were involved in conduction of the study and data collection.

DZ and NW performed the statistical analysis.

DZ, RZ, MS and NW wrote the manuscript.

All authors have read and approved the last version of the manuscript.

Data sharing statement

All raw data is available in the supplementary appendix.

Tables

CHADS₂ score	2 (1-3)
CHA₂DS₂-VASc score	4 (2-5)
Congestive heart failure	14 (15%)
Hypertension	75 (82%)
Age > 75 years	48 (53%)
Diabetes mellitus	18 (20%)
Stroke or TIA	15 (17%)
Vascular disease	27 (30%)
Age 65-75 years	25 (28%)
Female Sex	41 (45%)
HAS-BLED-Score	2 (1-2)
Hypertension (systolic blood pressure > 160 mmHg)	42 (46%)
Abnormal kidney / liver function	8 (9%)
Stroke	14 (15%)
Bleeding	1 (1%)
Labile INR values	1 (1%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Elderly (age > 65 years)	72 (79%)
Drugs or alcohol (1 point)	16 (18%)
Drugs and alcohol (2 points)	2 (2%)

Table 1. CHA₂DS₂-VASc and HAS-BLED Scores and individual risk factors. TIA: transient ischaemic attack; INR: international normalized ratio.

For peer review only

References

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;31(19):2369-429. doi: 10.1093/eurheartj/ehq278
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). *Eur Heart J* 2016 doi: 10.1093/eurheartj/ehw210
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama* 2001;285(18):2370-5. [published Online First: 2001/05/10]
4. Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. *BMJ* 2007;335(7609):24-7. doi: 10.1136/bmj.39246.581169.80
5. Spatz ES, Krumholz HM, Moulton BW. The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making. *Jama* 2016;315(19):2063-4. doi: 10.1001/jama.2016.3070 [published Online First: 2016/04/22]
6. Deyo RA. A key medical decision maker: the patient. *BMJ* 2001;323(7311):466-7.
7. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. *Curr Pharm Des* 2015;21(5):533-43.
8. Health literacy: report of the Council on Scientific Affairs. Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association. *Jama* 1999;281(6):552-7. [published Online First: 1999/02/18]
9. Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health outcomes: an updated systematic review. *Ann Intern Med* 2011;155(2):97-107. doi: 10.7326/0003-4819-155-2-201107190-00005
10. Wilke T, Bauer S, Mueller S, et al. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. *Patient* 2016 doi: 10.1007/s40271-016-0185-9 [published Online First: 2016/07/28]
11. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137(2):263-72. doi: 10.1378/chest.09-1584

- 1
2
3 12. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED)
4 to assess 1-year risk of major bleeding in patients with atrial fibrillation: the
5 Euro Heart Survey. *Chest* 2010;138(5):1093-100. doi: 10.1378/chest.10-0134
6
- 7 13. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
8 management of patients with atrial fibrillation: a report of the American College
9 of Cardiology/American Heart Association Task Force on Practice Guidelines
10 and the Heart Rhythm Society. *J Am Coll Cardiol* 2014;64(21):e1-76. doi:
11 10.1016/j.jacc.2014.03.022
12
- 13 14. Potpara TS, Pison L, Larsen TB, et al. How are patients with atrial fibrillation
14 approached and informed about their risk profile and available therapies in
15 Europe? Results of the European Heart Rhythm Association Survey.
16 *Europace* 2015;17(3):468-72. doi: 10.1093/europace/euv025 [published
17 Online First: 2015/02/28]
18
- 19 15. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid
20 regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a
21 randomized controlled trial. *JAMA* 1999;282(8):737-43.
22
- 23 16. McDowell M, Rebitschek FG, Gigerenzer G, et al. A Simple Tool for
24 Communicating the Benefits and Harms of Health Interventions: A Guide for
25 Creating a Fact Box. *MDM Policy & Practice* 2016;1(1):1-10. doi:
26 10.1177/2381468316665365
27
- 28 17. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared
29 decision making: the pace quickens. *BMJ* 2015;350:g7624. doi:
30 10.1136/bmj.g7624
31
- 32 18. van der Pol M, Hennessy D, Manns B. The role of time and risk preferences in
33 adherence to physician advice on health behavior change. *The European
34 journal of health economics : HEPAC : health economics in prevention and
35 care* 2016 doi: 10.1007/s10198-016-0800-7 [published Online First:
36 2016/04/18]
37
- 38 19. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral
39 Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With
40 Atrial Fibrillation. *J Am Heart Assoc* 2016;5(2) doi: 10.1161/jaha.115.003074
41 [published Online First: 2016/02/26]
42
- 43 20. Aliot E, Breithardt G, Brugada J, et al. An international survey of physician and
44 patient understanding, perception, and attitudes to atrial fibrillation and its
45 contribution to cardiovascular disease morbidity and mortality. *Europace*
46 2010;12(5):626-33. doi: 10.1093/europace/euq109
47
- 48 21. Zhao S, Zhao H, Wang X, et al. Factors influencing medication knowledge and
49 beliefs on warfarin adherence among patients with atrial fibrillation in China.
50 *Patient preference and adherence* 2017;11:213-20. doi: 10.2147/ppa.s120962
51 [published Online First: 2017/02/23]
52
- 53 22. Lloyd AJ. The extent of patients' understanding of the risk of treatments. *Qual
54 Health Care* 2001;10 Suppl 1:i14-8.
55
56
57
58
59
60

- 1
2
3 23. LaHaye SA, Gibbens SL, Ball DG, et al. A clinical decision aid for the selection of
4 antithrombotic therapy for the prevention of stroke due to atrial fibrillation. *Eur*
5 *Heart J* 2012;33(17):2163-71. doi: 10.1093/eurheartj/ehs167
6
- 7 24. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with
8 atrial fibrillation: comparison of two established bleeding prediction schemes in
9 a nationwide cohort. *J Thromb Haemost* 2011;9(8):1460-7. doi:
10 10.1111/j.1538-7836.2011.04378.x
11
- 12 25. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent
13 stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*
14 2007;146(12):857-67.
15
- 16 26. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
17 antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five
18 randomized controlled trials. *Arch Intern Med* 1994;154(13):1449-57.
19
- 20 27. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of
21 anticoagulant and thrombolytic treatment: American College of Chest
22 Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*
23 2008;133(6 Suppl):257S-98S. doi: 10.1378/chest.08-0674
24
- 25 28. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation:
26 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
27 College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
28 *Chest* 2012;141(2 Suppl):e531S-75S. doi: 10.1378/chest.11-2304
29
- 30 29. Mukaka M. A guide to appropriate use of Correlation coefficient in medical
31 research. *Malawi Medical Journal : The Journal of Medical Association of*
32 *Malawi* 2012;24(3):69-71.
33
- 34 30. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal
35 oral anticoagulation. *The American journal of managed care* 2004;10(14
36 Suppl):S451-58; discussion S58-61. [published Online First: 2005/02/09]
37
- 38 31. Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and
39 nonadherence in patients with atrial fibrillation: a commercial insurer
40 perspective. *Journal of managed care pharmacy : JMCP* 2013;19(4):302-16.
41 doi: 10.18553/jmcp.2013.19.4.302 [published Online First: 2013/05/01]
42
- 43 32. Ali AN, Howe J, Abdel-Hafiz A. Cost of acute stroke care for patients with atrial
44 fibrillation compared with those in sinus rhythm. *PharmacoEconomics*
45 2015;33(5):511-20. doi: 10.1007/s40273-015-0263-1 [published Online First:
46 2015/02/20]
47
- 48 33. Lang C, Seyfang L, Ferrari J, et al. Do Women With Atrial Fibrillation Experience
49 More Severe Strokes? Results From the Austrian Stroke Unit Registry. *Stroke*
50 2017 doi: 10.1161/strokeaha.116.015900 [published Online First: 2017/02/06]
51
- 52 34. King RB. Quality of life after stroke. *Stroke* 1996;27(9):1467-72. [published Online
53 First: 1996/09/01]
54
55
56
57
58
59
60

- 1
2
3 35. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of
4 atrial fibrillation and anticoagulant therapy: effects of an educational
5 intervention programme. The West Birmingham Atrial Fibrillation Project. *Int J*
6 *Cardiol* 2006;110(3):354-8. doi: 10.1016/j.ijcard.2005.07.031
7
8 36. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with
9 anticoagulation: A case-control study. *Am J Med* 1997;103(1):11-7.
10
11 37. Dantas GC, Thompson BV, Manson JA, et al. Patients' perspectives on taking
12 warfarin: qualitative study in family practice. *BMC Fam Pract* 2004;5:15. doi:
13 10.1186/1471-2296-5-15
14
15 38. Lip GY, Agnelli G, Thach AA, et al. Oral anticoagulation in atrial fibrillation: A pan-
16 European patient survey. *Eur J Intern Med* 2007;18(3):202-8. doi:
17 10.1016/j.ejim.2006.11.005
18
19 39. Lip GY, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial
20 fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation
21 Project. *Stroke* 2002;33(1):238-42.
22
23 40. McCabe PJ, Schad S, Hampton A, et al. Knowledge and self-management
24 behaviors of patients with recently detected atrial fibrillation. *Heart Lung*
25 2008;37(2):79-90. doi: 10.1016/j.hrtlng.2007.02.006
26
27 41. Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, et al. Patients' and
28 physicians' perceptions and attitudes about oral anticoagulation and atrial
29 fibrillation: a qualitative systematic review. *BMC Fam Pract* 2017;18(1):3. doi:
30 10.1186/s12875-016-0574-0 [published Online First: 2017/01/15]
31
32 42. Charles C, Whelan T, Gafni A. What do we mean by partnership in making
33 decisions about treatment? *BMJ* 1999;319(7212):780-2.
34
35 43. Borg Xuereb C, Shaw RL, Lane DA. Patients' and health professionals' views and
36 experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative
37 meta-synthesis. *Patient Educ Couns* 2012;88(2):330-7. doi:
38 10.1016/j.pec.2012.05.011 [published Online First: 2012/06/29]
39
40 44. LaHaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards
41 stroke prevention and bleeding risk in atrial fibrillation. *Thromb Haemost*
42 2014;111(3):465-73. doi: 10.1160/TH13-05-0424
43
44 45. Fuller R, Dudley N, Blacktop J. Risk communication and older people-
45 understanding of probability and risk information by medical inpatients aged 75
46 years and older. *Age Ageing* 2001;30(6):473-6. [published Online First:
47 2001/12/18]
48
49 46. Vandvik PO, Brandt L, Alonso-Coello P, et al. Creating clinical practice guidelines
50 we can trust, use, and share: a new era is imminent. *Chest* 2013;144(2):381-9.
51 doi: 10.1378/chest.13-0746
52
53 47. Clarkesmith DE, Pattison HM, Lip GY, et al. Educational intervention improves
54 anticoagulation control in atrial fibrillation patients: the TREAT randomised
55 trial. *PLoS One* 2013;8(9):e74037. doi: 10.1371/journal.pone.0074037
56
57
58
59
60

- 1
2
3 48. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision
4 making for antithrombotic therapy: a systematic review: Antithrombotic
5 Therapy and Prevention of Thrombosis, 9th ed: American College of Chest
6 Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2
7 Suppl):e1S-23S. doi: 10.1378/chest.11-2290
8
9
10 49. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between
11 perspectives of physicians and patients on anticoagulation in patients with
12 atrial fibrillation: observational study. *BMJ* 2001;323(7323):1218-22.
13
14 50. Alonso-Coello P, Montori VM, Diaz MG, et al. Values and preferences for oral
15 antithrombotic therapy in patients with atrial fibrillation: physician and patient
16 perspectives. *Health Expect* 2014;18:2318-27. doi: 10.1111/hex.12201
17
18 51. National Clinical Guideline Centre. National Institute for Health and Clinical
19 Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation.
20 London: National Institute for Health and Care Excellence (UK) 2014.
21
22 52. Hendriks JM, Crijns HJ, Tieleman RG, et al. The atrial fibrillation knowledge
23 scale: development, validation and results. *Int J Cardiol* 2013;168(2):1422-8.
24 doi: 10.1016/j.ijcard.2012.12.047
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: CHA₂DS₂-VASc and HAS-BLED scores of individual patients, including our classification into low, intermediate, high and very high stroke risk groups (stratified by CHA₂DS₂-VASc score).

107x83mm (600 x 600 DPI)

For peer review only




Figure 2: Correlation of CHA₂DS₂-VASc score and subjective assessed stroke risk.

107x82mm (600 x 600 DPI)

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Correlation of HAS-BLED score and subjective assessed bleeding risk.

107x83mm (600 x 600 DPI)

Peer Review Only




Figure 4: Amount of correct answered assessment of stroke risk in patients with different self-assessed levels of information.

437x349mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Mind the gap - atrial fibrillation patients and their physicians perceive risk and benefits of stroke prevention differently

David Zweiker¹, Robert Zweiker¹, Konstantina Roesch¹, Martin Schumacher²,
Vinzenc Stepan³, Peter Krippel⁴, Norbert Bauer⁵, Martin Heine⁶, Gerhard Reicht⁷,
Gudrun Zweiker⁸, Martin Sprenger⁹, Norbert Watzinger^{10*}

¹ Division of Cardiology, Department of Internal Medicine, Medical University of Graz,
Graz, Austria

² Department of Internal Medicine, Hospital Barmherzige Brueder Marschallgasse,
Graz, Austria

³ Department of Internal Medicine, Hospital Elisabethinen, Graz, Austria

⁴ Department of Internal Medicine, LKH Fürstenfeld, Krankenhausverbund Feldbach-
Fürstenfeld, Fürstenfeld, Austria

⁵ Department of Internal Medicine, LKH Hartberg, Hartberg, Austria

⁶ Department of Neurology, LKH Feldbach, Krankenhausverbund Feldbach-
Fürstenfeld, Feldbach, Austria

⁷ Department of Internal Medicine, Hospital Barmherzige Brueder Eggenberg, Graz,
Austria

⁸ General Practitioner, Straden, Austria

⁹ Department of Social Medicine and Epidemiology, Medical University of Graz, Graz,
Austria

¹⁰ Department of Internal Medicine, LKH Feldbach, Krankenhausverbund Feldbach-
Fürstenfeld, Feldbach, Austria

* Corresponding author:

Norbert Watzinger, MD

Department of Internal Medicine, LKH Feldbach

Krankenhausverbund Feldbach-Fürstenfeld

Ottokar-Kernstock-Strasse 18

8330 Feldbach

Austria

email: norbert.watzinger@lkh-feldbach.at

phone: +43 3152 899 3201

fax: +43 3152 899 3209

Supplemental material

Supplemental tables**Part I: To be completed by the patient**

1) How do you judge the risk of stroke without anticoagulation?

- a) Low
- b) Intermediate
- c) High
- d) Very high

2) How do you judge the efficacy of the proposed therapy? How strong is the effect of anticoagulation to avoid a stroke?

- a) Low
- b) Intermediate
- c) High
- d) Very high

3) The bleeding risk depends on comorbidities. How do you judge the risk of severe haemorrhagic complications within one year?

- a) Low
- b) Intermediate
- c) High
- d) Very high

4) How do you judge the disadvantages of treatment? How do you think increases the risk of severe haemorrhage if you take your medication appropriately?

- a) Low
- b) Intermediate
- c) High
- d) Very high

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

5) Would you discontinue anticoagulation therapy if minor bleedings would occur (e.g. haematoma, epistaxis, gum bleeding)

- a) Yes
- b) No
- c) I don't know

6) What do you fear more: stroke or bleeding complications?

- a) Stroke
- b) Bleeding
- c) I don't know

7) How do judge your general level of information regarding the disease "Atrial fibrillation" and the proposed therapy?

- a) Good
- b) Okay
- c) Improvable
- d) Bad

Part II: To be completed by the physician

1) Demographics

- a) Age (years):
- b) Gender: female/male
- c) Education: compulsory school/apprenticeship/vocational school/grammar school/vocational school with higher entrance qualification/university of applied sciences/university of general sciences

2) Planned type of anticoagulation

- a) Vitamin K antagonist (VKA)
- b) NOAC

- 1
2
3
4
5
6
7
- c) Low molecular weight heparin
 - d) Combination with antiplatelet

8
9

3) CHA₂DS₂-VASc score

- 10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- a) C = Congestive heart failure / LV dysfunction
 - b) H = Hypertension
 - c) A₂ = Age ≥ 75 years
 - d) D = Diabetes mellitus
 - e) S₂ = Stroke/TIA/thrombo-embolism
 - f) V = Vascular disease
 - g) A = Age 65-74 years
 - h) S = Sex category (i.e. female sex)

29
30

4) HAS-BLED Score

- 31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- a) H = Uncontrolled hypertension (systolic blood pressure > 160 mmHg)
 - b) A = Abnormal renal function (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 mmol/L) or abnormal liver function (chronic hepatic disease [e.g. cirrhosis] or biochemical evidence of significant hepatic derangement [e.g. bilirubin 2 x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase .3 x upper limit normal]) (1 point each)
 - c) S = Stroke
 - d) B = Bleeding (previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anaemia)
 - e) L = Labile INRs (unstable/high INRs or poor time in therapeutic range [e.g. < 60%])

f) D = Drugs or alcohol (concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflammatory drugs, or alcohol abuse) (1 point each)

Supplemental table S1. Questionnaire (English translation). LV: left ventricle; TIA: transitory ischaemic attack; INR: international normalized range

Patients per centre	
LKH Feldbach, Department of Internal Medicine	36 (40%)
Medical University of Graz, Division of Cardiology	18 (20%)
BHB Graz-Marschallgasse, Department of Internal Medicine	9 (10%)
KH Elisabethinen Graz, Department of Internal Medicine	8 (9%)
LKH Feldbach, Department of Neurology	6 (7%)
LKH Fürstenfeld, Department of Internal Medicine	5 (6%)
LKH Hartberg, Department of Internal Medicine	5 (6%)
BHB Graz-Eggenberg, Department of Internal Medicine	2 (2%)
Zweiker, MD, General Practitioner	2 (2%)
Highest completed education (ISCED level)	
Lower secondary education (2)	32 (35%)
Upper secondary vocational education (3B)	25 (28%)
Upper secondary general education (3A)	8 (9%)

Upper secondary vocational education (3C)	4 (4%)
Tertiary general education (5A)	3 (3%)
Post-secondary non-tertiary vocational education (4A)	2 (2%)
Tertiary vocational education (5A)	1 (1%)

Supplemental table S2. Demographics of included patients. ISCED: International Standard Classification of Education.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Information can be found in page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7;10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	16
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up	9

was addressed

Case-control study—If applicable, explain how matching of cases and controls was addressed

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses 9

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10-12
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Not applicable
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Not applicable
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	10-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-12
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Transparency declaration

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

Association between subjective risk perception and objective risk estimation in atrial fibrillation patients: a cross-sectional study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018242.R1
Article Type:	Research
Date Submitted by the Author:	17-Aug-2017
Complete List of Authors:	Zweiker, David; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Zweiker, Robert; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Winkler, Elisabeth; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Roesch, Konstantina; Medizinische Universitat Graz, Division of Cardiology, Department of Internal Medicine Schumacher, Martin; Krankenhaus Barmherzige Bruder Graz, Department of Internal Medicine Stepan, Vinzenz; Krankenhaus der Elisabethinen, Department of Internal Medicine Krippel, Peter; Landeskrankenhaus Furstenfeld, Department of Internal Medicine Bauer, Norbert; Landeskrankenhaus Hartberg, Department of Internal Medicine Heine, Martin; Landeskrankenhaus Feldbach, Department of Neurology Reicht, Gerhard; Krankenhaus Barmherzige Bruder Graz-Eggenberg Zweiker, Gudrun; General Practitioner Sprenger, Martin; Medizinische Universitat Graz, Department of Social Medicine and Epidemiology Watzinger, Norbert; Landeskrankenhaus Feldbach, Department of Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Anticoagulation < HAEMATOLOGY, CARDIOLOGY, Cardiology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 **Association between subjective risk perception and**
5
6
7 **objective risk estimation in atrial fibrillation patients: a**
8
9
10 **cross-sectional study.**
11

12
13 David Zweiker¹, Robert Zweiker¹, Elisabeth Winkler¹, Konstantina Roesch¹, Martin
14 Schumacher², Vinzenz Stepan³, Peter Krippel⁴, Norbert Bauer⁵, Martin Heine⁶,
15
16 Gerhard Reich⁷, Gudrun Zweiker⁸, Martin Sprenger⁹, Norbert Watzinger^{10*}
17
18
19

20
21 ¹ Division of Cardiology, Department of Internal Medicine, Medical University of Graz,
22
23 Graz, Austria
24

25
26 ² Department of Internal Medicine, Hospital Barmherzige Brueder Marschallgasse,
27
28 Graz, Austria
29

30
31 ³ Department of Internal Medicine, Hospital Elisabethinen, Graz, Austria
32

33
34 ⁴ Department of Internal Medicine, LKH Fürstenfeld, Krankenhausverbund Feldbach-
35
36 Fürstenfeld, Fürstenfeld, Austria
37

38
39 ⁵ Department of Internal Medicine, LKH Hartberg, Hartberg, Austria
40

41
42 ⁶ Department of Neurology, LKH Feldbach, Krankenhausverbund Feldbach-
43
44 Fürstenfeld, Feldbach, Austria
45

46
47 ⁷ Department of Internal Medicine, Hospital Barmherzige Brueder Eggenberg, Graz,
48
49 Austria
50

51
52 ⁸ General Practitioner, Straden, Austria
53

54
55 ⁹ Department of Social Medicine and Epidemiology, Medical University of Graz, Graz,
56
57 Austria
58

59
60 ¹⁰ Department of Internal Medicine, LKH Feldbach, Krankenhausverbund Feldbach-
Fürstenfeld, Feldbach, Austria

1
2
3 * Corresponding author:
4

5 Norbert Watzinger, MD
6

7 Department of Internal Medicine, LKH Feldbach
8

9 Krankenhausverbund Feldbach-Fürstenfeld
10

11 Ottokar-Kernstock-Strasse 18
12

13 8330 Feldbach
14

15 Austria
16

17
18 email: norbert.watzinger@lkh-feldbach.at
19

20
21 phone: +43 3152 899 3201
22

23 fax: +43 3152 899 3209
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective

Oral anticoagulation (OAC) is state-of-the-art therapy for atrial fibrillation (AF), the most common arrhythmia worldwide. However, little is known about the perception of AF patients and how it correlates with risk scores used by their physicians. Therefore, we correlated patients' estimates of their own stroke and bleeding risk with the objectively predicted individual risk using CHA₂DS₂-VASc and HAS-BLED scores.

Design

Cross-sectional prevalence study using convenience sampling and telephone follow up.

Settings

Eight hospital departments and one general practitioner in Austria. Patients' perception of stroke and bleeding risk was opposed to commonly used risk scoring.

Participants

Patients with newly diagnosed AF and indication for anticoagulation.

Main Outcome Measures

Comparison of subjective risk perception with CHA₂DS₂-VASc and HAS-BLED scores showing possible discrepancies between subjective and objective risk estimation. Patients' judgement of their own knowledge on AF and education were also correlated with accuracy of subjective risk appraisal.

Results

1
2
3 Ninety-one patients (age 73±11 years, 45% female) were included in this study.
4
5 Subjective stroke and bleeding risk estimation did not correlate with risk scores
6
7 ($\rho=0.08$ and $\rho=0.17$). The majority of patients (57%) underestimated the individual
8
9 stroke risk. Patients feared stroke more than bleeding (67% vs. 10%). There was no
10
11 relationship between accurate perception of stroke and bleeding risks and education
12
13 level. However, we found a correlation between the patients' judgement of their own
14
15 knowledge of AF and correct assessment of individual stroke risk ($\rho=0.24$, $\rho=0.02$).
16
17 During follow up, patients experienced the following events: death (n=5), stroke
18
19 (n=2), bleeding (n=1). OAC discontinuation rate despite indication was 3%.
20
21
22
23

24 **Conclusions**

25
26
27 In this cross-sectional analysis of OAC-naïve AF patients, we found major differences
28
29 between patients' perceptions and physicians' assessments of risks and benefits of
30
31 OAC. To ensure shared decision-making and informed consent, more attention
32
33 should be given to evidence-based and useful communication strategies.
34
35
36

37 **Trial registration**

38
39
40 NCT03061123
41
42

43 **Key words**

44
45
46
47 Atrial fibrillation, oral anticoagulation, questionnaire, self-assessment
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Strengths and limitations

- The design of this cross-sectional study allowed the objective assessment of the patients' risk perception immediately after initiation of anticoagulation for atrial fibrillation.
- For generalizability, primary, secondary and tertiary health care centres were included in this study.
- To evaluate long-time outcome, follow up was obtained via telephone.
- The study is statistically powered for the cross-sectional comparison, but the number of patients included does not allow association between baseline characteristics and events during follow up.

Introduction

Atrial fibrillation (AF) is the most common significant arrhythmia worldwide, associated with a fivefold increase in risk for stroke¹ and almost doubles the risk of mortality.² In an ageing population, the number of individuals affected is projected to increase exponentially over the next decades.³ Since the early 1990's, oral anticoagulation (OAC) is the state-of-the-art therapy for reducing stroke and embolic events.² OAC is considered a long-term, often lifelong medical intervention. Therefore, clinicians and particularly patients need to have a clear understanding of the related benefits and immanent harms.⁴ It serves as a reasonable background for shared-decision making of patients and their doctors, one of the most important principles for patients' reliance, compliance and adherence to recommended medical strategies.^{5,6}

Adequate information of patients⁷ and increased health literacy⁸ are of major importance for compliance and adherence to therapy. Patients' knowledge also affects the perception of risk for stroke, embolic events and bleeding. It has been shown that the extent of information perceived influenced patients' preferences towards or against OAC treatment the most.⁹

Clinicians use algorithms like CHA₂DS₂-VASc and HAS-BLED scores¹⁰⁻¹² to predict the balance of future risk for stroke and embolic events versus bleeding in an individual patient. A recent survey of the European Heart Rhythm Association proved that a considerable amount of time and resources are needed in daily clinical practice to communicate risk / benefit ratios to patients suffering from AF: Several centres have established special OAC clinics and initial visits mostly lasted 21-30 minutes.¹³ However, decades after the introduction of OAC therapy, standardised and validated

1
2
3 risk communication tools¹⁴⁻¹⁶ are still missing and adherence follow-up programmes
4
5 are rare.¹³ Those programmes have an important impact on effectiveness of OAC:
6
7 Adherence to OAC is considered a key factor for preventing events,¹⁷ but it is still as
8
9 low as 43%.¹⁸
10

11
12 Little is known about the perception of AF patients and how it correlates with risk
13
14 scores used by their physicians.¹⁹ A potential gap between subjective and objective
15
16 assessments may increase the likelihood of non-compliance to OAC in AF patients.²⁰
17
18 Therefore, the study was designed to correlate the subjective stroke and bleeding
19
20 risk with the objectively predicted individual risks calculated by CHA₂DS₂-VASc and
21
22 HAS-BLED scores.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

This work is a cross-sectional prevalence study, using convenience sampling by trained doctors at nine centres (representing primary, secondary and tertiary health care) in the province of Styria, Austria. Responsible institutional review boards approved the study (1376/2015 [BHB Graz, Austria], 28-004 ex 15/16 [Medical University of Graz, Austria]). Furthermore, the study was registered under the ClinicalTrials.gov number NCT03061123. Patients with first diagnosed and ECG-documented non-valvular AF and indication for OAC were included in the study. Exclusion criteria were pre-existing OAC therapy, valvular heart disease, history of valve surgery, denial or inability of informed consent.

This study was designed to comply with standard operating procedures of individual centres for initiation of OAC therapy. Responsible physicians were asked to include all eligible patients. Immediately after the pre-treatment interviews, which included the discussion of benefits, harms and side effects of OAC, patients were asked to participate in the study. After informed consent was signed, a standardized questionnaire was handed out to all patients (supplemental table S1).

Questionnaire

The survey was conducted using a standardized questionnaire with two parts (supplemental table S1). The patient-oriented part consisted of seven questions covering subjective perception of patients with regard to general individual risk/benefit ratios of OAC in AF, the willingness of therapy continuation even in the possible case of minor adverse effects (haematoma, minor bleeding) and the individually discerned level of information. We used 3- and 4-point verbal rating scales to comply with the patients' categorical perception of checks and balances.²¹

1
2
3 Physicians in charge of patients filled the second part, which included patient
4 demographics, CHA₂DS₂-VASc and HAS-BLED scores, as well as the intended OAC
5 therapy.
6
7

8
9
10 CHA₂DS₂-VASc and HAS-BLED scores were stratified into four risk categories each
11 corresponding to the four different risk levels for stroke/embolic events and bleeding
12 interrogated by the patient questionnaire. Risk estimations were based on published
13 data from large population studies. Regarding CHA₂DS₂-VASc score, patients with
14 zero points (stroke rate 0-1%/year) were considered *low risk*, one point (stroke rate 1-
15 2%/year) *intermediate risk*, 2-4 points (stroke rate 2-7%/year) *high risk* and ≥ 5 points
16 (stroke rate $> 7\%$ /year) *very high risk* cohort.^{10 22 23} The corresponding categories
17 concerning HAS-BLED score were as follows: no or one risk factor (*low risk* group,
18 bleeding rate 0-4%/year), two risk factors (*intermediate risk* group, bleeding rate 4-
19 6%/year), 3 or 4 risk factors (*high risk* group, bleeding rate 6-10%/year) and 5 or
20 more risk factors (*very high risk* group, bleeding rate $> 10\%$ /year).^{11 22}
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 For assessing the awareness of general benefit of OAC, we asked patients to
37 estimate their appraisal of relative risk reduction (RRR) for stroke and embolic
38 events. We defined *high* (RRR 50-74%) as an accurate answer,²⁴ others were
39 *low* (RRR 0-24%), *intermediate* (RRR 25-49%) and *very high* (RRR 75-100%). We
40 extrapolated predicted hazard ratios (HR) of bleeding due to OAC from meta-
41 analyses²⁴⁻²⁷ and defined the general risk of OAC as *intermediate* (HR 1.25-1.49).
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Other options were *low* (HR 1.00-1.24), *high* (HR 1.50-2.00) and *very high* (HR $>$
2.00). Subjective scales were interpreted as “correct” if they corresponded correctly
to individual objective risk groups.

Follow up

Follow up was obtained by phone calls. Patients were asked about their current status of OAC therapy and the occurrence of cardiovascular or bleeding events.

Statistical analysis

Sample size calculation was performed using the freeware tool G*Power by Heinrich Heine University Düsseldorf (<http://www.gpower.hhu.de>). We sought to oppose the self-reported benefits and risks of OAC with an actual assessment using validated data (including CHA₂DS₂-VASc Score and HAS-BLED Score). To prove correlation ($|\rho| < 0.3$) with type I error (α) of 0.05 and power ($1 - \beta$) of 80%, at least 84 patients had to be included into the study.

Two-sided significance level was 0.05. Data are presented as mean \pm standard deviation, median (interquartile range) or count (proportion), where appropriate. Pearson's test and Spearman's rank correlation coefficient were used to correlate ordinal variables (e.g. subjective perceptions and risk scores). Correlation coefficients (i.e. $|r|$, $|\rho|$) were interpreted as follows: negligible correlation (0.0-0.3), low correlation (0.3-0.5), moderate correlation (0.5-0.8) and strong correlation (0.8-1.0).²⁸

Data were analysed with IBM® SPSS® Statistics version 23 (IBM Corporation, Armonk, NY). All raw data can be found in the supplemental file.

Results

Patient population

From September 2015 to March 2016, 91 patients (age 73 ± 11 years, 45% female) from nine centres were included in this study (supplemental table S2). As highest educational attainment, lower secondary education (ISCED level 2, $n=32$, 35%) and higher secondary vocational education (ISCED level 3B $n=25$, 28%) were most prevalent. New oral anticoagulants (NOACs) were used most frequently ($n=75$, 82%). vitamin K antagonists ($n=14$, 15%) and low-molecular weight heparin ($n=2$, 2%) were given to remaining patients.

Objective risk estimation

Median CHA₂DS₂-VASc-Score was 4 (interquartile range 2-5). Therefore, we summarized most patients on high risk for stroke or embolic events (CHA₂DS₂-VASc score 2-4, stroke risk 2-7%/year, figure 1). Most common risk factors were arterial hypertension and age > 75 years (table 1). In terms of HAS-BLED score, most of patients were in low (0-1 points, bleeding risk 0–4 %) and intermediate risk groups (2 points, bleeding risk 4–6 %; figure 1).

Perception of individual risk

Many patients ($n=41$, 45%) interpreted risk for stroke and embolic events in atrial fibrillation as *high* (corresponding stroke risk 2-7% per year). Bleeding risk was estimated mainly as *intermediate* (corresponding bleeding risk 4-6% per year, $n=40$, 44%). Patients feared stroke more than bleeding (67% vs. 10%) and only 9% would discontinue OAC therapy if minor bleeding complications (e.g. epistaxis) would occur.

1
2
3 Patients estimated their personal level of information as *good* or *adequate* in 41%
4
5 and 34%, respectively.
6
7

8 **Correlations**

9

10
11 Patients estimated their risk for stroke or embolic events in concordance to the
12
13 individual CHA₂DS₂-VASc score in 28% (n=25) of cases, but by the majority (n=52,
14
15 57%) risk was underrated. Bleeding risk was assumed accurately in 41% (n=37), but
16
17 overestimated in 31 cases (34%). There were no significant correlations neither
18
19 between objectively assessed and subjectively expected risk for stroke nor for
20
21 bleeding ($p=0.08$, $p=0.47$, figure 2 and $p<0.01$, $p=0.98$, figure 3).
22
23
24

25
26 Analogies in patients' answers and CHA₂DS₂-VASc and HAS-BLED scores did not
27
28 correlate to the levels of highest education ($p=-0.06$, $p=0.64$ and $p=0.17$, $p=0.15$).
29
30 However, we observed a significant correlation between patients' judgement of their
31
32 knowledge of AF with regard to concordant assumptions of stroke risk and CHA₂DS₂-
33
34 VASc score ($p=0.24$, $p=0.02$, figure 4). No correlation was observed between
35
36 patients' judgement of AF knowledge and concordance with subjectively assumed
37
38 and objectively predicted risk for bleeding events ($p=0.08$, $p=0.45$).
39
40
41

42 **Perception of general risk**

43

44
45 Most patients (n=51, 56%) assumed score-predicted effectiveness of OAC in AF as
46
47 *high* (corresponding stroke risk reduction 50-74%). Other answers were *very high*
48
49 (RRR 75-100%; n=23, 25%), *intermediate* (RRR 25-49%; n=15, 17%) or *low* (RRR 0-
50
51 24%; n=1, 1%). The estimated general risk of bleeding caused by OAC was
52
53 considered by patients as *intermediate* (HR for bleeding 1.25-1.49; n=37, 41%) and
54
55
56
57
58
59
60

1
2
3 *low* (HR 1.00-1.24; n=30, 33%). Only 3 patients (3%) estimated the bleeding risk
4
5 associated with OAC as *very high* (HR > 2.00).
6
7

8 ***Follow up***

9
10
11 Follow up via telephone was obtained 18±2 months after enrolment from 84 patients
12
13 (92%). The remaining 7 patients were lost to follow up because of missing contact
14
15 details (n=6, 7%) or denial to participate (n=1, 1%). The following events were
16
17 reported during follow up: death of unknown cause (n=5, 5%), ischaemic stroke (n=2,
18
19 2%) and epistaxis requiring hospitalization (n=1, 1%). All patients with ischaemic or
20
21 bleeding events were under OAC therapy and had continued it until follow up.
22
23
24

25
26 At time of follow up, four patients had discontinued OAC therapy intermittently (n=1,
27
28 1%) or permanently (n=3, 3%). One female patient with CHA₂DS₂-VASc score of 2
29
30 reported that OAC therapy was terminated due to successful pulmonary vein isolation
31
32 without any recurrence of AF during 9 months of event recorder monitoring. Three
33
34 patients (CHA₂DS₂-VASc score between 3 and 7) discontinued OAC therapy on their
35
36 own; although one patient reinitiated OAC therapy after discussion with his general
37
38 practitioner.
39
40
41

42
43 Patients, who stopped OAC therapy on their own, believed that their current condition
44
45 “had no indication” for OAC therapy. Two of them had underestimated their individual
46
47 stroke risk at baseline interrogation, while one had overestimated it. Two stoppers
48
49 feared the risk of bleeding more than the risk for ischemic events.
50
51
52
53
54
55
56
57
58
59
60

Discussion

This cross-sectional questionnaire study in 91 OAC-naïve patients with non-valvular AF shows that (1) patients generally underestimated their risk of stroke, (2) they perceived their individual stroke risk to higher extent than bleeding risk and (3) there was a significant correlation between accuracy in answers and patients' judgement of their knowledge of AF. During follow up, we observed OAC discontinuation despite clear indication in 3% of patients.

Due to the high prevalence of AF in the western world, non-adherence to OAC in AF patients has a tremendous impact on our society. Despite the availability of adequate therapy, AF-related strokes are still estimated to cost eight billion USD annually in the United States^{29 30} or over 9,000 GBP per stroke in the UK.³¹ The increased severity of AF-related strokes compared to other etiologies³² may even increase the negative effect of general embolic events on quality of life.³³ As a consequence, it is urgently necessary to ameliorate adherence to OAC therapy for AF. We proved underjudgement of stroke risk and therefore, postulate better patient education as a possibility to overcome this problem.

No correlation between subjective assessment and objective risk

To our knowledge, this is the first study that compares the subjective risk perception of AF patients with evidence-based risk scores used in daily clinical practice. We found no significant correlation between subjective and objective assessment of stroke or bleeding risk. Therefore, our study provides evidence that a perception gap remains after informed consent discussion before OAC initiation. Although not powered for it, we provide preliminary data on the OAC discontinuation rate one year

1
2
3 after OAC initiation. Two of three patients, who stopped OAC on their own, had
4
5 underestimated their stroke risk at baseline.
6
7

8
9 If this finding remains constant in larger trials, it has a direct impact on clinical
10
11 practice. A perception gap between subjective and objective assessment of stroke or
12
13 bleeding risk is considered a major obstacle at the start of a lifelong medical
14
15 intervention. It hinders not only shared decision making, but may also worsen
16
17 treatment compliance and adherence.³⁴
18
19

20
21 Previous studies already evaluated the levels of information in patients after initiation
22
23 of OAC treatment.^{19 35-39} In a survey of 711 AF patients that were on OAC for at least
24
25 one year, only 7% knew the purpose of anticoagulation in AF.³⁸ Lane et al.³⁵
26
27 observed that 51% of AF patients with OAC therapy for ≥ 3 months could not name
28
29 their cardiac condition. Furthermore, the knowledge could not be increased by a brief
30
31 educational intervention. McCabe et al.⁴⁰ showed considerable knowledge deficits
32
33 already two weeks after initial diagnosis of AF. A recent qualitative systematic review
34
35 postulated the lack of patient information as one of the most important reasons for
36
37 VKA underuse.⁴¹
38
39

40
41 Although Dantas et al.³⁷ demonstrated that only minimal knowledge of patients is
42
43 needed to allow acceptance of OAC, doctors should seek shared decisions. This is
44
45 even more important, when evidence for drug treatment is marginal,⁴² which is
46
47 definitely not the case in patients with high risk scores for AF.² However, the
48
49 physician's perspective of shared decision making may not be congruent to the
50
51 patient's perceptions.⁴³ LaHaye et al.⁴⁴ demonstrated high interpatient variability
52
53 regarding individual treatment thresholds. Consequently, we propose that health
54
55 literacy of patients should be enhanced before OAC initiation, especially regarding
56
57 the individual risk/benefit ratio. Thus, patients may be able to participate in decision-
58
59
60

1
2
3 making of therapy initiation. Patients also seem to have difficulties regarding verbal
4 descriptions of risk.⁴⁵ Therefore, graphical information might help overcome this
5
6 problem.^{7 14} One promising example is an electronic prototype for the translation of
7
8 Grading of Recommendations Assessment, Development and Evaluation (GRADE)
9
10 summaries⁴⁶ into decision aids using interactive formats to present evidence
11
12 summaries at varying levels of detail.¹⁶ Another possibility is the establishment of a
13
14 Fact Box, which describes evidence of benefits and harms without making
15
16 recommendations.¹⁵ Further theory-driven educational interventions have been
17
18 shown to increase OAC control⁴⁷ or knowledge of INR targets.³⁵
19
20
21
22
23

24 ***Stroke risk is topping bleeding risk***

25
26
27 In our study, most of the patients assumed their personal stroke risk to be the most
28
29 frequent and serious complication of untreated atrial fibrillation in their setting.
30
31 However, the majority (57%) underestimated their stroke risk while 41% interpreted
32
33 their bleeding risk accurately. In other studies, patients were keen on avoiding stroke
34
35 more than bleeding⁴⁸ and placed even more importance on stroke prevention than
36
37 doctors⁴⁹ with higher tolerance of adverse bleeding events.⁵⁰ Nevertheless, with
38
39 increased duration of OAC therapy, knowledge about OAC in the indication of AF
40
41 seems to deteriorate.³⁸
42
43
44
45

46 ***Factors influencing correct risk estimation***

47
48
49 We found out that the highest level of educational attainment did not correlate with
50
51 analogies in risk estimation in our analysis. Our results therefore indicate that
52
53 understanding of individuals' risk is not correlated with formal education levels.
54
55 However, the preservation of knowledge might be correlated with better education.⁴⁰
56
57
58
59
60

1
2
3 Lip et al.³⁹ showed differences of AF perceptions in different ethnical groups. We
4
5 could not add evidence to this factor as we included only Caucasian patients.
6
7

8 Patients that felt better informed had an improved understanding of their individual
9
10 risks in this study. Consequently, we encourage to evaluate patients' information
11
12 level repeatedly by asking how informed they felt and to take appropriate measures
13
14 to enhance the patient's level of information if required.
15
16

17 **Limitations**

18
19
20 Our study has several limitations. Firstly, due to the absence of a screening log,
21
22 consecutive patient enrolment cannot be guaranteed. Secondly, the study was
23
24 powered for cross sectional analysis, but not for associations association between
25
26 baseline parameters and OAC adherence or events at follow up. Therefore, we can
27
28 only speculate that higher levels of information might be associated with better
29
30 adherence and outcomes as results of previous studies suggested. Thirdly, we did
31
32 not evaluate other bleeding risk scores, such as ATRIA⁵¹ or ORBIT,⁵² into the
33
34 analysis. Lastly, we intended to concentrate on the risk perception of individual
35
36 patients and did not evaluate the general knowledge of AF and stroke prevention per
37
38 se in a standardized questionnaire.⁵³ Due to this fact, we kept the questionnaire short
39
40 and tried to minimize bias due to selection of motivated patients that may not be
41
42 representative of the general AF population.¹⁹
43
44
45
46
47
48

49 **Conclusion**

50
51
52 In this cross-sectional analysis of OAC-naïve AF patients, we found major differences
53
54 between patients' perceptions and physicians' assessments of risks and benefits of
55
56
57
58
59
60

1
2
3 OAC. To ensure shared decision-making and informed consent, more attention
4
5 should be given to evidence-based and useful communication strategies.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We appreciate the helpful assistance of Mr. Stefan Zweiker in the preparation of the manuscript. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

Dr. Bauer reports personal fees from Bayer, Medtronic, Daiichi-Sankyo, Servier, personal fees from Bayer, AstraZeneca, other from Boehringer-Ingelheim, Bayer, Lilly outside the submitted work.

Dr. Heine has nothing to disclose.

Dr. Krippel has nothing to disclose.

Dr. Reicht has nothing to disclose.

Dr. Schumacher has nothing to disclose.

Dr. Sprenger has nothing to disclose.

Dr. Stepan has nothing to disclose.

Dr. Watzinger reports personal fees from Lectures, personal fees from Consulting, outside the submitted work.

Ms. Winkler has nothing to disclose.

Dr. Zweiker D has nothing to disclose.

Dr. Zweiker G has nothing to disclose.

1
2
3 Dr. Zweiker R reports grants from Lilly, personal fees from Boehringer Ingelheim,
4 personal fees from Bayer, personal fees from Daiichi-Sankyo, outside the submitted
5 work.
6
7
8
9

10 **Contributorship statement**

11
12
13
14 RZ, MS and NW designed the study.

15
16 RZ, EW, KR, MS, VS, PK, NB, MH, GR, GZ, MS and NW were involved in
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
conduction of the study and data collection.

DZ and NW performed the statistical analysis.

DZ, RZ, MS and NW wrote the manuscript.

All authors have read and approved the last version of the manuscript.

30 **Data sharing statement**

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
All raw data is available in the supplementary appendix.

Tables

CHADS₂ score	2 (1-3)
CHA₂DS₂-VASc score	4 (2-5)
CHA ₂ DS ₂ -VASc score \geq 2	81 (89%)
Congestive heart failure	14 (15%)
Hypertension (diagnosis of arterial hypertension)	75 (82%)
Age > 75 years	48 (53%)
Diabetes mellitus	18 (20%)
Stroke or TIA	15 (17%)
Vascular disease	27 (30%)
Age 65-75 years	25 (28%)
Female Sex	41 (45%)
HAS-BLED score	2 (1-2)
HAS-BLED score \geq 3	17 (19%)
Hypertension (systolic blood pressure > 160 mmHg)	42 (46%)
Abnormal kidney / liver function	8 (9%)
Stroke	14 (15%)

Bleeding	1 (1%)
Labile INR values	1 (1%)
Elderly (age > 65 years)	72 (79%)
Drugs or alcohol (1 point)	16 (18%)
Drugs and alcohol (2 points)	2 (2%)

Table 1. CHA₂DS₂-VASc and HAS-BLED Scores and individual risk factors. TIA: transient ischaemic attack; INR: international normalized ratio.

References

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;31(19):2369-429. doi: 10.1093/eurheartj/ehq278
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). *Eur Heart J* 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210 [published Online First: 2016/08/28]
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama* 2001;285(18):2370-5. [published Online First: 2001/05/10]
4. Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. *BMJ* 2007;335(7609):24-7. doi: 10.1136/bmj.39246.581169.80
5. Spatz ES, Krumholz HM, Moulton BW. The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making. *Jama* 2016;315(19):2063-4. doi: 10.1001/jama.2016.3070 [published Online First: 2016/04/22]
6. Deyo RA. A key medical decision maker: the patient. *BMJ* 2001;323(7311):466-7.
7. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. *Curr Pharm Des* 2015;21(5):533-43.
8. Health literacy: report of the Council on Scientific Affairs. Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association. *Jama* 1999;281(6):552-7. [published Online First: 1999/02/18]
9. Wilke T, Bauer S, Mueller S, et al. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. *Patient* 2016 doi: 10.1007/s40271-016-0185-9 [published Online First: 2016/07/28]
10. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137(2):263-72. doi: 10.1378/chest.09-1584
11. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138(5):1093-100. doi: 10.1378/chest.10-0134

- 1
2
3 12. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
4 management of patients with atrial fibrillation: a report of the American College
5 of Cardiology/American Heart Association Task Force on Practice Guidelines
6 and the Heart Rhythm Society. *J Am Coll Cardiol* 2014;64(21):e1-76. doi:
7 10.1016/j.jacc.2014.03.022
8
- 9
10 13. Potpara TS, Pison L, Larsen TB, et al. How are patients with atrial fibrillation
11 approached and informed about their risk profile and available therapies in
12 Europe? Results of the European Heart Rhythm Association Survey.
13 *Europace* 2015;17(3):468-72. doi: 10.1093/europace/euv025 [published
14 Online First: 2015/02/28]
15
- 16 14. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid
17 regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a
18 randomized controlled trial. *JAMA* 1999;282(8):737-43.
19
- 20 15. McDowell M, Rebitschek FG, Gigerenzer G, et al. A Simple Tool for
21 Communicating the Benefits and Harms of Health Interventions: A Guide for
22 Creating a Fact Box. *MDM Policy & Practice* 2016;1(1):1-10. doi:
23 10.1177/2381468316665365
24
- 25 16. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared
26 decision making: the pace quickens. *BMJ* 2015;350:g7624. doi:
27 10.1136/bmj.g7624
28
- 29
30 17. van der Pol M, Hennessy D, Manns B. The role of time and risk preferences in
31 adherence to physician advice on health behavior change. *The European*
32 *journal of health economics : HEPAC : health economics in prevention and*
33 *care* 2016 doi: 10.1007/s10198-016-0800-7 [published Online First:
34 2016/04/18]
35
- 36 18. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral
37 Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With
38 Atrial Fibrillation. *J Am Heart Assoc* 2016;5(2) doi: 10.1161/jaha.115.003074
39 [published Online First: 2016/02/26]
40
- 41 19. Aliot E, Breithardt G, Brugada J, et al. An international survey of physician and
42 patient understanding, perception, and attitudes to atrial fibrillation and its
43 contribution to cardiovascular disease morbidity and mortality. *Europace*
44 2010;12(5):626-33. doi: 10.1093/europace/euq109
45
- 46 20. Zhao S, Zhao H, Wang X, et al. Factors influencing medication knowledge and
47 beliefs on warfarin adherence among patients with atrial fibrillation in China.
48 *Patient preference and adherence* 2017;11:213-20. doi: 10.2147/ppa.s120962
49 [published Online First: 2017/02/23]
50
- 51 21. Lloyd AJ. The extent of patients' understanding of the risk of treatments. *Qual*
52 *Health Care* 2001;10 Suppl 1:i14-8.
53
- 54 22. LaHaye SA, Gibbens SL, Ball DG, et al. A clinical decision aid for the selection of
55 antithrombotic therapy for the prevention of stroke due to atrial fibrillation. *Eur*
56 *Heart J* 2012;33(17):2163-71. doi: 10.1093/eurheartj/ehs167
57
58
59
60

- 1
2
3 23. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with
4 atrial fibrillation: comparison of two established bleeding prediction schemes in
5 a nationwide cohort. *J Thromb Haemost* 2011;9(8):1460-7. doi:
6 10.1111/j.1538-7836.2011.04378.x
7
- 8 24. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent
9 stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*
10 2007;146(12):857-67.
11
- 12 25. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
13 antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five
14 randomized controlled trials. *Arch Intern Med* 1994;154(13):1449-57.
15
- 16 26. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of
17 anticoagulant and thrombolytic treatment: American College of Chest
18 Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*
19 2008;133(6 Suppl):257S-98S. doi: 10.1378/chest.08-0674
20
- 21 27. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation:
22 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
23 College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
24 *Chest* 2012;141(2 Suppl):e531S-75S. doi: 10.1378/chest.11-2304
25
- 26 28. Mukaka M. A guide to appropriate use of Correlation coefficient in medical
27 research. *Malawi Medical Journal : The Journal of Medical Association of*
28 *Malawi* 2012;24(3):69-71.
29
- 30 29. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal
31 oral anticoagulation. *The American journal of managed care* 2004;10(14
32 Suppl):S451-58; discussion S58-61. [published Online First: 2005/02/09]
33
- 34 30. Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and
35 nonadherence in patients with atrial fibrillation: a commercial insurer
36 perspective. *Journal of managed care pharmacy : JMCP* 2013;19(4):302-16.
37 doi: 10.18553/jmcp.2013.19.4.302 [published Online First: 2013/05/01]
38
- 39 31. Ali AN, Howe J, Abdel-Hafiz A. Cost of acute stroke care for patients with atrial
40 fibrillation compared with those in sinus rhythm. *PharmacoEconomics*
41 2015;33(5):511-20. doi: 10.1007/s40273-015-0263-1 [published Online First:
42 2015/02/20]
43
- 44 32. Lang C, Seyfang L, Ferrari J, et al. Do Women With Atrial Fibrillation Experience
45 More Severe Strokes? Results From the Austrian Stroke Unit Registry. *Stroke*
46 2017 doi: 10.1161/strokeaha.116.015900 [published Online First: 2017/02/06]
47
- 48 33. King RB. Quality of life after stroke. *Stroke* 1996;27(9):1467-72. [published Online
49 First: 1996/09/01]
50
- 51 34. Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health
52 outcomes: an updated systematic review. *Ann Intern Med* 2011;155(2):97-107.
53 doi: 10.7326/0003-4819-155-2-201107190-00005
54
- 55
56
57
58
59
60

- 1
2
3 35. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of
4 atrial fibrillation and anticoagulant therapy: effects of an educational
5 intervention programme. The West Birmingham Atrial Fibrillation Project. *Int J*
6 *Cardiol* 2006;110(3):354-8. doi: 10.1016/j.ijcard.2005.07.031
7
- 8 36. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with
9 anticoagulation: A case-control study. *Am J Med* 1997;103(1):11-7.
10
- 11 37. Dantas GC, Thompson BV, Manson JA, et al. Patients' perspectives on taking
12 warfarin: qualitative study in family practice. *BMC Fam Pract* 2004;5:15. doi:
13 10.1186/1471-2296-5-15
14
- 15 38. Lip GY, Agnelli G, Thach AA, et al. Oral anticoagulation in atrial fibrillation: A pan-
16 European patient survey. *Eur J Intern Med* 2007;18(3):202-8. doi:
17 10.1016/j.ejim.2006.11.005
18
- 19 39. Lip GY, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial
20 fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation
21 Project. *Stroke* 2002;33(1):238-42.
22
- 23 40. McCabe PJ, Schad S, Hampton A, et al. Knowledge and self-management
24 behaviors of patients with recently detected atrial fibrillation. *Heart Lung*
25 2008;37(2):79-90. doi: 10.1016/j.hrtlng.2007.02.006
26
- 27 41. Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, et al. Patients' and
28 physicians' perceptions and attitudes about oral anticoagulation and atrial
29 fibrillation: a qualitative systematic review. *BMC Fam Pract* 2017;18(1):3. doi:
30 10.1186/s12875-016-0574-0 [published Online First: 2017/01/15]
31
- 32 42. Charles C, Whelan T, Gafni A. What do we mean by partnership in making
33 decisions about treatment? *BMJ* 1999;319(7212):780-2.
34
- 35 43. Borg Xuereb C, Shaw RL, Lane DA. Patients' and health professionals' views and
36 experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative
37 meta-synthesis. *Patient Educ Couns* 2012;88(2):330-7. doi:
38 10.1016/j.pec.2012.05.011 [published Online First: 2012/06/29]
39
- 40 44. LaHaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards
41 stroke prevention and bleeding risk in atrial fibrillation. *Thromb Haemost*
42 2014;111(3):465-73. doi: 10.1160/TH13-05-0424
43
- 44 45. Fuller R, Dudley N, Blacktop J. Risk communication and older people-
45 understanding of probability and risk information by medical inpatients aged 75
46 years and older. *Age Ageing* 2001;30(6):473-6. [published Online First:
47 2001/12/18]
48
- 49 46. Vandvik PO, Brandt L, Alonso-Coello P, et al. Creating clinical practice guidelines
50 we can trust, use, and share: a new era is imminent. *Chest* 2013;144(2):381-9.
51 doi: 10.1378/chest.13-0746
52
- 53 47. Clarkesmith DE, Pattison HM, Lip GY, et al. Educational intervention improves
54 anticoagulation control in atrial fibrillation patients: the TREAT randomised
55 trial. *PLoS One* 2013;8(9):e74037. doi: 10.1371/journal.pone.0074037
56
57
58
59
60

- 1
2
3 48. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision
4 making for antithrombotic therapy: a systematic review: Antithrombotic
5 Therapy and Prevention of Thrombosis, 9th ed: American College of Chest
6 Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2
7 Suppl):e1S-23S. doi: 10.1378/chest.11-2290
8
- 9
10 49. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between
11 perspectives of physicians and patients on anticoagulation in patients with
12 atrial fibrillation: observational study. *BMJ* 2001;323(7323):1218-22.
13
- 14 50. Alonso-Coello P, Montori VM, Diaz MG, et al. Values and preferences for oral
15 antithrombotic therapy in patients with atrial fibrillation: physician and patient
16 perspectives. *Health Expect* 2014;18:2318-27. doi: 10.1111/hex.12201
17
- 18 51. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-
19 associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial
20 Fibrillation) Study. *J Am Coll Cardiol* 2011;58(4):395-401. doi:
21 10.1016/j.jacc.2011.03.031 [published Online First: 2011/07/16]
22
- 23 52. O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple
24 bedside score to assess bleeding risk in atrial fibrillation. *Eur Heart J*
25 2015;36(46):3258-64. doi: 10.1093/eurheartj/ehv476 [published Online First:
26 2015/10/02]
27
- 28
29 53. Hendriks JM, Crijns HJ, Tieleman RG, et al. The atrial fibrillation knowledge
30 scale: development, validation and results. *Int J Cardiol* 2013;168(2):1422-8.
31 doi: 10.1016/j.ijcard.2012.12.047
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1: CHA₂DS₂-VASc and HAS-BLED scores of individual patients, including our classification into low, intermediate, high and very high stroke risk groups (stratified by CHA₂DS₂-VASc score).

Figure 2: Correlation of CHA₂DS₂-VASc score and subjective assessed stroke risk.

Figure 3: Correlation of HAS-BLED score and subjective assessed bleeding risk.

Figure 4: Amount of correct answered assessment of stroke risk in patients with different self-assessed levels of information.




Figure 1: CHA₂DS₂-VASc and HAS-BLED scores of individual patients, including our classification into low, intermediate, high and very high stroke risk groups (stratified by CHA₂DS₂-VASc score).

107x83mm (600 x 600 DPI)

For peer review only




Figure 2: Correlation of CHA₂DS₂-VASc score and subjective assessed stroke risk.

107x82mm (600 x 600 DPI)

Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Correlation of HAS-BLED score and subjective assessed bleeding risk.

107x83mm (600 x 600 DPI)

Peer Review Only




Figure 4: Amount of correct answered assessment of stroke risk in patients with different self-assessed levels of information.

162x129mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Association between subjective risk perception and objective risk estimation in atrial fibrillation patients: a cross-sectional study.

David Zweiker¹, Robert Zweiker¹, Elisabeth Winkler¹, Konstantina Roesch¹, Martin Schumacher², Vinzenz Stepan³, Peter Krippel⁴, Norbert Bauer⁵, Martin Heine⁶, Gerhard Reicht⁷, Gudrun Zweiker⁸, Martin Sprenger⁹, Norbert Watzinger^{10*}

¹ Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

² Department of Internal Medicine, Hospital Barmherzige Brueder Marschallgasse, Graz, Austria

³ Department of Internal Medicine, Hospital Elisabethinen, Graz, Austria

⁴ Department of Internal Medicine, LKH Fürstenfeld, Krankenhausverbund Feldbach-Fürstenfeld, Fürstenfeld, Austria

⁵ Department of Internal Medicine, LKH Hartberg, Hartberg, Austria

⁶ Department of Neurology, LKH Feldbach, Krankenhausverbund Feldbach-Fürstenfeld, Feldbach, Austria

⁷ Department of Internal Medicine, Hospital Barmherzige Brueder Eggenberg, Graz, Austria

⁸ General Practitioner, Straden, Austria

⁹ Department of Social Medicine and Epidemiology, Medical University of Graz, Graz, Austria

¹⁰ Department of Internal Medicine, LKH Feldbach, Krankenhausverbund Feldbach-Fürstenfeld, Feldbach, Austria

* Corresponding author:

Norbert Watzinger, MD

Department of Internal Medicine, LKH Feldbach

Krankenhausverbund Feldbach-Fürstenfeld

Ottokar-Kernstock-Strasse 18

8330 Feldbach

Austria

email: norbert.watzinger@lkh-feldbach.at

phone: +43 3152 899 3201

fax: +43 3152 899 3209

Supplemental material

Supplemental tables**Part I: To be completed by the patient**

1) How do you judge the risk of stroke without anticoagulation?

- a) Low
- b) Intermediate
- c) High
- d) Very high

2) How do you judge the efficacy of the proposed therapy? How strong is the effect of anticoagulation to avoid a stroke?

- a) Low
- b) Intermediate
- c) High
- d) Very high

3) The bleeding risk depends on comorbidities. How do you judge the risk of severe haemorrhagic complications within one year?

- a) Low
- b) Intermediate
- c) High
- d) Very high

4) How do you judge the disadvantages of treatment? How do you think increases the risk of severe haemorrhage if you take your medication appropriately?

- a) Low
- b) Intermediate
- c) High
- d) Very high

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

5) Would you discontinue anticoagulation therapy if minor bleedings would occur (e.g. haematoma, epistaxis, gum bleeding)

- a) Yes
- b) No
- c) I don't know

6) What do you fear more: stroke or bleeding complications?

- a) Stroke
- b) Bleeding
- c) I don't know

7) How do judge your general level of information regarding the disease "Atrial fibrillation" and the proposed therapy?

- a) Good
- b) Okay
- c) Improvable
- d) Bad

Part II: To be completed by the physician

1) Demographics

- a) Age (years):
- b) Gender: female/male
- c) Education: compulsory school/apprenticeship/vocational school/grammar school/vocational school with higher entrance qualification/university of applied sciences/university of general sciences

2) Planned type of anticoagulation

- a) Vitamin K antagonist (VKA)
- b) NOAC

- 1
2
3
4
5
6
7
- c) Low molecular weight heparin
 - d) Combination with antiplatelet

8
9

3) CHA₂DS₂-VASc score

- 10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- a) C = Congestive heart failure / LV dysfunction
 - b) H = Hypertension
 - c) A₂ = Age ≥ 75 years
 - d) D = Diabetes mellitus
 - e) S₂ = Stroke/TIA/thrombo-embolism
 - f) V = Vascular disease
 - g) A = Age 65-74 years
 - h) S = Sex category (i.e. female sex)

29
30

4) HAS-BLED Score

- 31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- a) H = Uncontrolled hypertension (systolic blood pressure > 160 mmHg)
 - b) A = Abnormal renal function (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 mmol/L) or abnormal liver function (chronic hepatic disease [e.g. cirrhosis] or biochemical evidence of significant hepatic derangement [e.g. bilirubin 2 x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase .3 x upper limit normal]) (1 point each)
 - c) S = Stroke
 - d) B = Bleeding (previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anaemia)
 - e) L = Labile INRs (unstable/high INRs or poor time in therapeutic range [e.g. < 60%])

f) D = Drugs or alcohol (concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflammatory drugs, or alcohol abuse) (1 point each)

Supplemental table S1. Questionnaire (English translation). LV: left ventricle; TIA: transitory ischaemic attack; INR: international normalized range

Patients per centre	
LKH Feldbach, Department of Internal Medicine	36 (40%)
Medical University of Graz, Division of Cardiology	18 (20%)
BHB Graz-Marschallgasse, Department of Internal Medicine	9 (10%)
KH Elisabethinen Graz, Department of Internal Medicine	8 (9%)
LKH Feldbach, Department of Neurology	6 (7%)
LKH Fürstenfeld, Department of Internal Medicine	5 (6%)
LKH Hartberg, Department of Internal Medicine	5 (6%)
BHB Graz-Eggenberg, Department of Internal Medicine	2 (2%)
Zweiker, MD, General Practitioner	2 (2%)
Highest completed education (ISCED level)	
Lower secondary education (2)	32 (35%)
Upper secondary vocational education (3B)	25 (28%)
Upper secondary general education (3A)	8 (9%)

Upper secondary vocational education (3C)	4 (4%)
Tertiary general education (5A)	3 (3%)
Post-secondary non-tertiary vocational education (4A)	2 (2%)
Tertiary vocational education (5A)	1 (1%)

Supplemental table S2. Demographics of included patients. ISCED: International Standard Classification of Education.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Information can be found in page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	17
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up	10

was addressed

Case-control study—If applicable, explain how matching of cases and controls was addressed

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses 10

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	11-13
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Not applicable
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Not applicable
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	11-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-13
		(b) Report category boundaries when continuous variables were categorized	11-13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	14-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Transparency declaration

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only